VKT Pharma Private Limited

VKT Pharma Private Limited, established on May 31, 2006, is a privately held pharmaceutical company headquartered in Hyderabad, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U24100TG2006PTC050221. As of March 31, 2025, VKT Pharma reported an authorized capital of ₹12.00 crore and a paid-up capital of ₹11.06 crore. The company employs approximately 238 professionals, reflecting its commitment to quality and innovation in the pharmaceutical sector.

VKT Pharma specializes in the development, manufacturing, and marketing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is primarily focused on the gastrointestinal therapeutic category, with Famotidine and Ranitidine being the top exported products. In 2022, VKT Pharma's total export value was $8.9 million USD, encompassing 179 shipments across two products. Famotidine led the market with a 15.5% share, while Ranitidine held a 1.7% share.

VKT Pharma operates a state-of-the-art manufacturing facility located in Derasam Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh. This plant is equipped to produce high volumes of solid dosage forms, including tablets, capsules, and ready-to-fill immediate or modified release pellets. The facility adheres to stringent quality standards, ensuring compliance with current Good Manufacturing Practices (cGMP) and other regulatory requirements.

The leadership team at VKT Pharma is headed by Managing Director Vamsi Krishna Potluri, who has been instrumental in steering the company's strategic direction and growth. Other key executives include Ramesh Babu Potluri and Hima Bindu Potluri, both serving as Directors. Their combined expertise and vision have been pivotal in establishing VKT Pharma as a significant player in the pharmaceutical industry.

VKT Pharma has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully undergone audits by the US FDA and EU GMP, achieving compliance with their stringent standards. In 2018, VKT Pharma received WHO GMP accreditation, further solidifying its commitment to quality. These regulatory approvals have facilitated the company's entry into these markets, enabling it to offer a range of pharmaceutical products that meet international quality standards.

VKT Pharma has also focused on penetrating emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO prequalification status has been instrumental in gaining access to these regions, allowing it to supply essential medicines that meet global quality standards. This strategic approach has enabled VKT Pharma to address the growing demand for affordable and high-quality pharmaceuticals in these markets.

VKT Pharma's geographic strategy demonstrates a balanced approach, with a strong focus on both regulated and emerging markets. The company's significant export value of $8.9 million USD in 2022, primarily from Famotidine and Ranitidine, indicates a concentrated product portfolio. While this concentration offers specialization, it also presents risks associated with dependency on a limited number of products. VKT Pharma's expansion into diverse geographic regions aims to mitigate these risks and leverage growth opportunities across different markets.

VKT Pharma has achieved FDA facility registrations, demonstrating its compliance with US regulatory standards. The company has also filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access in the United States. Additionally, VKT Pharma has submitted Drug Master Files (DMFs), providing detailed information about its manufacturing processes and quality controls. The company's facilities have undergone FDA inspections, reflecting its commitment to maintaining high-quality manufacturing practices.

VKT Pharma holds WHO GMP accreditation, affirming its adherence to international manufacturing standards. The company has also successfully passed EU GMP audits, ensuring its products meet the quality requirements of the European market. These certifications underscore VKT Pharma's dedication to producing pharmaceuticals that comply with global quality benchmarks.

In India, VKT Pharma operates under the guidelines set by the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulatory standards. VKT Pharma also possesses export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to VKT Pharma. This absence suggests that the company maintains a strong compliance record with regulatory authorities.

VKT Pharma operates in a competitive landscape with several key players in the gastrointestinal therapeutic category. While specific market share data is not publicly disclosed, VKT Pharma's focus on high-quality formulations and adherence to international standards positions it favorably against competitors. The company's strategic expansion into both regulated and emerging markets further enhances its competitive edge.

VKT Pharma's key differentiators include its vertically integrated business model, encompassing research and development, manufacturing, and marketing of pharmaceutical products. The company's commitment to quality is evident through its compliance with cGMP and international certifications such as WHO GMP and EU GMP. Additionally, VKT Pharma's focus on novel drug delivery systems and contract research and manufacturing services (CRAMS) allows it to offer innovative solutions to its clients.

VKT Pharma's current strategic direction emphasizes the development of generic formulations, with a particular focus on complex molecules and novel drug delivery systems. The company's expansion into both regulated and emerging markets reflects its commitment to global growth and accessibility. Looking ahead, VKT Pharma aims to strengthen its position in the global pharmaceutical industry by leveraging its integrated capabilities and dedication to quality.

VKT Pharma has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's export volume of $8.9 million USD in 2022, with 179 shipments, indicates reliability and capacity. VKT Pharma's adherence to international quality standards and regulatory approvals further underscores its dependability as a supplier.

Importers should verify the following certifications to ensure product quality and compliance:

• FDA Facility Registration: Confirm VKT Pharma's registration status with the US FDA to ensure compliance with US regulations.

• WHO GMP Accreditation: Verify the company's WHO GMP certification to ensure adherence to international manufacturing standards.

• EU GMP Certification: Check for EU GMP certification to confirm compliance with European Union quality standards.

• ISO Certifications: Review ISO certifications related to quality management systems to assess the company's commitment to quality.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting VKT Pharma directly.

When considering VKT Pharma as a supplier, importers should undertake the following due diligence steps:

• Verify Regulatory Certifications: Ensure that VKT Pharma holds the necessary certifications for the target market.

• Assess Manufacturing Facilities: Evaluate the company's manufacturing facilities for compliance with cGMP and other relevant standards.

• Review Financial Stability: Analyze the company's financial statements to assess stability and capacity for large orders.

• Check Compliance History: Investigate any past regulatory actions or compliance issues.

• Evaluate Product Quality: Request samples and conduct quality assessments to ensure product standards meet requirements.

Red flags to watch for include discrepancies in certification details, unresolved regulatory issues, and inconsistent product quality. Recommended pre-order checks involve obtaining and verifying all relevant certifications, conducting facility audits, and reviewing recent financial statements.